<DOC>
	<DOCNO>NCT02585947</DOCNO>
	<brief_summary>The objective study analyze factor affect Hepatitis B Virus ( HBV ) reactivation anti-HBc positive patient Non-Hodgkin 's lymphoma treat rituximab compare HBV reactivation rate duration prophylactic treatment tenofovir contribute establishment effective prevention strategy .</brief_summary>
	<brief_title>To Compare Efficacy Prophylactic Use Tenofovir Duration Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>This study conduct randomize , open-label , multi-center design . On Day 1 chemotherapy , approximately 90 subject screen determine eligible randomize either Group A Group B 1:1 manner study participation . - Group A : Upon EOC , subject receive tenofovir 300mg approximately 6 month ( 24 week ) undergo treatment follow-up every 12 week 72 week post chemotherapy . - Group A : Upon EOC , subject receive tenofovir 300mg approximately 12 month ( 48 week ) undergo treatment follow-up every 12 week 72 week post chemotherapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . Age ≥ 18 ( Women must pregnant breastfeeding ; female childbearing potential must blood test urine study screen rule pregnancy . / A woman childbearing potential must use adequate method contraception avoid pregnancy throughout study 26 week last dose tenofovir . / If Investigator obtain information concern pregnancy female patient , Investigator must terminate study drug immediately patient , report information IRB manner SAE reporting ) 2 . CD 20 positive patient NonHodgkin 's lymphoma plan receive anticancer treatment rituximab base chemotherapy A. ECOG performance status 02 B . Adequate renal function : serum creatinine level &lt; 2 mg/dL ( 177 μmol/L ) C. Adequate hematological function : hemoglobin ≥ 9g/dL , absolute neutrophil count ( ANC ) ≥ 1,500/μL , platelet count ≥ 75,000/μL , unless abnormality due bone marrow involvement lymphoma D. Expected residual life ≥ 6 month 3 . Serum HBsAg negative , antiHCV negative , antiHBc positive 4 . ALT &lt; 80IU/mL , serum bilirubin &lt; 3.0mg/dL , unless abnormality due liver involvement lymphoma tumor lysis syndrome 5 . Individuals give understood detailed explanation study , voluntarily decide participate study , provide write informed consent 1 . ChildPugh class C 2 . Other chronic liver disease autoimmune hepatitis Wilson 's disease 3 . Patient hypersensitivity study drug 4 . Patient galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption 5 . Patient pregnant lactating . Or plan pregnant lactation study period even partner male patient</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>81 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Tenofovir</keyword>
</DOC>